top of page
SCIENTIFIC PUBLICATIONS
Stay at the forefront of precision oncology
Scientific insights, company news, and upcoming events from Altum Sequencing. Don't miss the opportunity to meet us at congresses, startup fairs, and international awareness days across the globe.
Identification of minimal residual disease using the TRACKseq (CloneSight) test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer
This prospective exploratory study evaluated a tumor-informed ctDNA assay for MRD detection in HR+ early breast cancer, showing potential for anticipating late relapse before clinical recurrence.
1 min read
Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
This study evaluated liquid biopsy-based MRD monitoring in AML using cfDNA and NGS, highlighting both its potential and the technical challenges that remain.
1 min read
Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease
This study showed that cfDNA genetic profiling from liquid biopsy can complement tissue biopsy for B-cell lymphoma diagnosis and PET/CT for MRD surveillance.
1 min read
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
This proof-of-principle study explored personalized ctDNA monitoring after CAR-T therapy in follicular lymphoma, showing potential value for response assessment and post-treatment surveillance.
1 min read
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
This real-life follicular lymphoma study showed that liquid biopsy MRD monitoring by ultra-deep sequencing complements PET/CT and helps identify patients at higher risk of progression.
1 min read
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
This study validated a deep targeted sequencing method for AML MRD monitoring, showing that sequencing-determined MRD positivity was associated with inferior disease-free and overall survival.
1 min read
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
This work analytically and clinically validated an in-house deep-sequencing workflow for MRD monitoring in multiple myeloma, demonstrating high applicability, sensitivity and prognostic value.
1 min read
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
This study established the prognostic value of deep sequencing-based MRD detection in multiple myeloma, showing that MRD negativity identifies patients with longer time to progression and overall survival.
1 min read
Stay in the Know
Subscribe for Updates
Get the latest science, events, and company news from Altum Sequencing delivered to your inbox. No spam, just precision oncology.
bottom of page